On the stock market since 1983, it operates in the world of money and finance. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
No real growth (-3% a year). Red columns mark years that ended in a loss.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades below its recent peak — about 12% off the top. A pullback, not a collapse.
The company sells $2.0M a year; the problem isn’t sales — it’s costs running above that number.
It pays out $0.37 per share each year — regular cash for whoever holds the stock.
A loss of $3.9M against $2.0M in annual sales.
The price action doesn’t yet back an upward turn. Council score: 0/10.
The sales tempo runs behind the sector. Council score: 4/10.
On our five-subject report card, DRNYX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: DRNYX is a small company that closed last year at a loss. The road back to profit runs through spending discipline.